Vistin Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Vistin Pharma has a total shareholder equity of NOK310.7M and total debt of NOK5.6M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are NOK387.9M and NOK77.2M respectively. Vistin Pharma's EBIT is NOK82.7M making its interest coverage ratio -20.1. It has cash and short-term investments of NOK5.6M.
Key information
1.8%
Debt to equity ratio
NOK 5.64m
Debt
| Interest coverage ratio | -20.1x |
| Cash | NOK 5.63m |
| Equity | NOK 310.74m |
| Total liabilities | NOK 77.21m |
| Total assets | NOK 387.94m |
Recent financial health updates
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Recent updates
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26Financial Position Analysis
Short Term Liabilities: VISTN's short term assets (NOK143.8M) exceed its short term liabilities (NOK67.4M).
Long Term Liabilities: VISTN's short term assets (NOK143.8M) exceed its long term liabilities (NOK9.8M).
Debt to Equity History and Analysis
Debt Level: VISTN's net debt to equity ratio (0%) is considered satisfactory.
Reducing Debt: VISTN's debt to equity ratio has increased from 0% to 1.8% over the past 5 years.
Debt Coverage: VISTN's debt is well covered by operating cash flow (1770%).
Interest Coverage: VISTN earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:50 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |